Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microba Life SciencesASX:MAP Earnings per Share (Diluted) is A$-0.04 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 157 Medical Diagnostics & Research companies, Microba Life Sciences ranks better than 52.23% on this metric.
During the past 3 years, the average EPS without NRIGrowth Rate was 12.30% per year.
During the past 4 years, Microba Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 12.30% per year. The lowest was 12.30% per year. And the median was 12.30% per year.
Microba Life Sciences (ASX:MAP) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Microba Life Sciences Earnings per Share (Diluted) Related Terms
Microba Life Sciences Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Microba Life Sciences's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences Earnings per Share (Diluted) Chart
ASX:MAP vs TMO, DHR, IDXX: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, Microba Life Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's PE Ratio falls into.
Microba Life Sciences Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Microba Life Sciences's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of A$-0.04 mean?
Microba Life Sciences (ASX:MAP) has a Earnings per Share (Diluted) of A$-0.04 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Microba Life Sciences and its competitors. According to the industry distribution chart, Microba Life Sciences ranks #75 out of 157 companies in the Medical Diagnostics & Research industry, placing it in the top 47.8%.
Is Microba Life Sciences' Earnings per Share (Diluted) too high?
Microba Life Sciences' current Earnings per Share (Diluted) is A$-0.04. Based on the distribution chart, Microba Life Sciences ranks #75 out of 157 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Microba Life Sciences' Earnings per Share (Diluted) compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #75 out of 157 companies for Earnings per Share (Diluted). This puts Microba Life Sciences in the upper half of its industry. The industry median Earnings per Share (Diluted) is 10.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 10.70, based on 157 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current Earnings per Share (Diluted) is A$-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.24, compared to a current price of A$0.06 — trading 75.8% below its estimated fair value. The current Earnings per Share (Diluted) is A$-0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Earnings per Share (Diluted) is A$-0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 
